Efficacy and Tolerability of Balneotherapy With Mineral Water Named" Debole of Vetriolo" in Fibromyalgia Syndrome (VET)
Primary Purpose
Fibromyalgia Syndrome
Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Balneotherapy
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Fibromyalgia Syndrome focused on measuring Fibromyalgia Syndrome, Balneotherapy, Vetriolo Water
Eligibility Criteria
Inclusion Criteria:
- Patients suffering from FS according to American College of Rheumatology (ACR) criteria for at least 3 months and with a stable treatment for at least 4 weeks
- Have a score of WPI≥7 and SS ≥ 5 or WPI 3-6 and SS≥9 screening and baseline visit
- Provide written informed consent to participate in the study
Exclusion Criteria:• Concurrent participation in other therapeutic trials
- Patients that have been treated with mud-pack therapy and/or balneotherapy in the last 6 months
- Patients affected by neoplastic diseases in the last five years, with cardiovascular disease of recent onset, suffering from serious impairment of hematopoietic, renal and hepatic systems
- Presence of concurrent autoimmune or inflammatory disease, such as, rheumatoid arthritis, systemic lupus erythematous, inflammatory bowel disease, etc.
- Pregnant and nursing mothers
- Severe psychiatric illnesses (current schizophrenia, major depression with suicidal ideation, within two years)
- Routine daily use of narcotic analgesics or history of substance abuse
- Patients unable to complete the questionnaires
Sites / Locations
- Fioravanti Antonella
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Balneotherapy
Placebo
Arm Description
Daily thermal-mineral bath with mineral water named "Debole of Vetriolo" for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)
daily thermal bath with tap water bath for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)
Outcomes
Primary Outcome Measures
Change of 20% of VAS score
VAS score,
Change of 20% Total FIQ
FIQ
Secondary Outcome Measures
Quality of life assessed by SF-12
SF-12
Anxiety evaluation by STAI
STAI
Depression assessed by CES-D
CES-D
Widespread Pain assessed by WPI
WPI
Symptom Severity assessed by SS scale
SS
Full Information
NCT ID
NCT02548065
First Posted
September 4, 2015
Last Updated
January 30, 2017
Sponsor
Azienda Ospedaliera Universitaria Senese
1. Study Identification
Unique Protocol Identification Number
NCT02548065
Brief Title
Efficacy and Tolerability of Balneotherapy With Mineral Water Named" Debole of Vetriolo" in Fibromyalgia Syndrome
Acronym
VET
Official Title
Efficacy and Tolerability of Balneotherapy With Mineral Water Named" Debole of Vetriolo" in Patients With Fibromyalgia Syndrome (FS): A Randomized Double Blind Controlled Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
April 1, 2015 (Actual)
Primary Completion Date
October 31, 2016 (Actual)
Study Completion Date
January 30, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Azienda Ospedaliera Universitaria Senese
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The present randomized, controlled double blind trial aims to evaluate the efficacy and tolerability of balneotherapy with mineral water named "Debole of Vetriolo" in 100 patients with primary Fibromyalgia Syndrome (FS).
Detailed Description
The fibromyalgia syndrome (FS) is a chronic condition that is characterized by chronic widespread pain, fatigue, sleep disorders, cognitive disturbances, physical and psychological distress. It was estimated that between 2.9 and 3.8% of the general population in Europe and the US are affected , with the majority of patients in clinical settings being female . Clinical research suggests that pharmacologic treatment alone is not the best approach for FS, and that an integrated approach that includes non-pharmacologic therapies along with pharmacologic therapies improves outcomes in these patients.
Balneotherapy is one of the most commonly used non-pharmacological approaches for SF, but it is still being discussed and its role in modern medicine is still not clear. The action mechanisms of thermal baths are not completely known, and it is difficult to distinguish the effects of thermal applications from the benefits that could be derived from a stay in a spa environment.
The present randomized, controlled double blind trial aims to evaluate the efficacy and tolerability of balneotherapy with mineral water named "Debole of Vetriolo" in patients with primary SF fulfilling the 2010 ACR criteria.
Following confirmation that the patients fulfill the screening criteria and having obtained written informed consent, 100 patients will be randomized 1:1 and allocated to one of two groups using a computer-generated table of random numbers:
Group I (50 patients) will be treated with daily thermal-mineral bath with mineral water named "Debole of Vetriolo" for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)
Group II (50 patients), the control group, will be treated with daily thermal bath with with tap water bath for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)
The block randomization list will be kept by individuals who have no contact with the investigators who assign patients to their randomized treatment, and who will not perform any patient assessment or conduct the statistical.
All patients will undergo general medical evaluation and rheumatologic examination by the same physician before the start of the study. All the demographic, anamnestic and clinical data will be collected on identical questionnaires. Each patient will be assessed at baseline time (T0), after 2 weeks (T1),after 3 months (T2), 6 months (T3), following the beginning of the study.
All assessments will be performed at Levico Terme Spa Centre by the same rheumatologist who will be blinded to which study arms the patients belongs. Laboratory analysis will be performed only at baseline.
Assessments at each examination will include:
Primary Outcome Measures
Visual Analogue Scale (VAS);
Fibromyalgia Impact Questionnaire total score (FIQ-Total) e Fibromyalgia Impact Questionnaire Physical score (FIQ-PI)
Secondary Outcome Measures
Widespread Pain Index (WPI)
Symptom Severity (SS)
Short Form Health Survey (SF-12)
State-Trait Anxiety Inventory (STAI)
Center for Epidemiologic Studies Depression Scale (CES-D)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibromyalgia Syndrome
Keywords
Fibromyalgia Syndrome, Balneotherapy, Vetriolo Water
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Balneotherapy
Arm Type
Active Comparator
Arm Description
Daily thermal-mineral bath with mineral water named "Debole of Vetriolo" for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
daily thermal bath with tap water bath for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)
Intervention Type
Other
Intervention Name(s)
Balneotherapy
Other Intervention Name(s)
spa therapy
Intervention Description
Bath with mineral water named "Debole of Vetriolo" at 36°C, 15 minutes for 12 consecutive days in bathtubs
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
Tap water
Intervention Description
Bath with Thermal tap water
Primary Outcome Measure Information:
Title
Change of 20% of VAS score
Description
VAS score,
Time Frame
change from baseline at 15 days
Title
Change of 20% Total FIQ
Description
FIQ
Time Frame
change from baseline at 15 days
Secondary Outcome Measure Information:
Title
Quality of life assessed by SF-12
Description
SF-12
Time Frame
Baseline time , after 2 weeks ,after 3 months, 6 months, following the beginning of the study.
Title
Anxiety evaluation by STAI
Description
STAI
Time Frame
Baseline time , after 2 weeks ,after 3 months, 6 months, following the beginning of the study.
Title
Depression assessed by CES-D
Description
CES-D
Time Frame
Baseline time , after 2 weeks ,after 3 months, 6 months, following the beginning of the study.
Title
Widespread Pain assessed by WPI
Description
WPI
Time Frame
Baseline time , after 2 weeks ,after 3 months, 6 months, following the beginning of the study.
Title
Symptom Severity assessed by SS scale
Description
SS
Time Frame
Baseline time , after 2 weeks ,after 3 months, 6 months, following the beginning of the study.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients suffering from FS according to American College of Rheumatology (ACR) criteria for at least 3 months and with a stable treatment for at least 4 weeks
Have a score of WPI≥7 and SS ≥ 5 or WPI 3-6 and SS≥9 screening and baseline visit
Provide written informed consent to participate in the study
Exclusion Criteria:• Concurrent participation in other therapeutic trials
Patients that have been treated with mud-pack therapy and/or balneotherapy in the last 6 months
Patients affected by neoplastic diseases in the last five years, with cardiovascular disease of recent onset, suffering from serious impairment of hematopoietic, renal and hepatic systems
Presence of concurrent autoimmune or inflammatory disease, such as, rheumatoid arthritis, systemic lupus erythematous, inflammatory bowel disease, etc.
Pregnant and nursing mothers
Severe psychiatric illnesses (current schizophrenia, major depression with suicidal ideation, within two years)
Routine daily use of narcotic analgesics or history of substance abuse
Patients unable to complete the questionnaires
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Antonella Fioravanti, MD
Organizational Affiliation
Azienda Ospedaliera Universitaria Senese
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fioravanti Antonella
City
Siena
ZIP/Postal Code
53100
Country
Italy
12. IPD Sharing Statement
Citations:
PubMed Identifier
22408369
Citation
Guidelli GM, Tenti S, De Nobili E, Fioravanti A. Fibromyalgia syndrome and spa therapy: myth or reality? Clin Med Insights Arthritis Musculoskelet Disord. 2012;5:19-26. doi: 10.4137/CMAMD.S8797. Epub 2012 Feb 22.
Results Reference
background
PubMed Identifier
11354556
Citation
Buskila D, Abu-Shakra M, Neumann L, Odes L, Shneider E, Flusser D, Sukenik S. Balneotherapy for fibromyalgia at the Dead Sea. Rheumatol Int. 2001 Apr;20(3):105-8. doi: 10.1007/s002960000085.
Results Reference
background
PubMed Identifier
11254234
Citation
Neumann L, Sukenik S, Bolotin A, Abu-Shakra M, Amir M, Flusser D, Buskila D. The effect of balneotherapy at the Dead Sea on the quality of life of patients with fibromyalgia syndrome. Clin Rheumatol. 2001;20(1):15-9. doi: 10.1007/s100670170097.
Results Reference
background
PubMed Identifier
12070676
Citation
Evcik D, Kizilay B, Gokcen E. The effects of balneotherapy on fibromyalgia patients. Rheumatol Int. 2002 Jun;22(2):56-9. doi: 10.1007/s00296-002-0189-8. Epub 2002 Mar 29.
Results Reference
background
PubMed Identifier
15965635
Citation
Donmez A, Karagulle MZ, Tercan N, Dinler M, Issever H, Karagulle M, Turan M. SPA therapy in fibromyalgia: a randomised controlled clinic study. Rheumatol Int. 2005 Dec;26(2):168-72. doi: 10.1007/s00296-005-0623-9. Epub 2005 Jun 17.
Results Reference
background
PubMed Identifier
17520260
Citation
Fioravanti A, Perpignano G, Tirri G, Cardinale G, Gianniti C, Lanza CE, Loi A, Tirri E, Sfriso P, Cozzi F. Effects of mud-bath treatment on fibromyalgia patients: a randomized clinical trial. Rheumatol Int. 2007 Oct;27(12):1157-61. doi: 10.1007/s00296-007-0358-x. Epub 2007 May 23.
Results Reference
background
PubMed Identifier
20461783
Citation
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010 May;62(5):600-10. doi: 10.1002/acr.20140.
Results Reference
result
PubMed Identifier
29730741
Citation
Fioravanti A, Manica P, Bortolotti R, Cevenini G, Tenti S, Paolazzi G. Is balneotherapy effective for fibromyalgia? Results from a 6-month double-blind randomized clinical trial. Clin Rheumatol. 2018 Aug;37(8):2203-2212. doi: 10.1007/s10067-018-4117-z. Epub 2018 May 5.
Results Reference
derived
Learn more about this trial
Efficacy and Tolerability of Balneotherapy With Mineral Water Named" Debole of Vetriolo" in Fibromyalgia Syndrome
We'll reach out to this number within 24 hrs